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ABSTRACT 
AIM OF THE STUDY: 
• To evaluate patients presenting with a breast lump and to evaluate 
them with clinical examination ,cytology and with MRI and interpret 
its findings- with regards to involvement of the opposite breast and 
axilla and level of infiltration and the sensitivity of the modality itself. 
• To establish that MRI breast can be made as a routine investigating 
modality in the management of breast cancer by comparing it with 
mammogram  
• To use MRI in detecting local site recurrences in patients with post 
MRM status presenting with pain /ulcers/nodules. 
• In this sample size of patients ,the p value did not turn out 
significant(0.94143) and hence the comparison was not statistically 
significant .However, recent studies conducted in a larger population 
have shown that MRI has a better tumour predictability by terms of 
sensitivity when compared to a mammogram.hence MRI scanning of 
the breast can be included in both screening and diagnosis for breast 
cancer in institutions where available , as it has various advantages 
over a mammogram like less radiation exposure ,use in younger age 
group, ability to add on level of infiltration and involvement of 
opposite breast and axilla.this one modality can guide the surgeon in 
deciding the treatment option in patients presenting afresh and post 
surgical patients  
 
 
INTRODUCTION: 
Dynamic MRI of the breast is viewed as an examination technique which 
is supplementary to mammography and sonogram and which can provide 
important additional diagnostic information. Accepted indications for MR 
mammogram include examination of patients who have undergone 
lumpectomy or mastectomy and patients having prosthetic breast 
implants. This method also appears to be useful for differentiation 
between postoperative scarring and carcinoma as well as to exclude a 
multicentric breast cancer prior to breast conserving surgery. The 
sensitivity of MR mammography, however is limited in cases of DCIS. 
After being diagnosed with breast cancer, a breast MRI may be 
performed to determine:  
 Size of the tumor and level of infiltration 
 The presence of multi centric lesions in the same breast & whether 
there is an undetected tumor in the opposite breast. 
 Lymph node metastasis to the opposite axilla 
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REVIEW OF LITERATURE: 
 KRIEGE ET AL studied 1909 women between twenty five and 
seventy years of age at 6 centers across Netherlands. After 3 rounds 
of screening 50 breast cancers were detected out of which 44 were 
invasive. 80% of these cancers were identified with MRI and thirty 
three% by a mammogram.43%percent of these tumours were less 
than 1 cm in size and 33% of them had spread to the axilla. 
However mammograms identified DCIS better than MRI and the 
specificity of both were 95% and 90 % respectively. 
 
 Leach et al studied 649 women between 35-49 years of age at 22 
centers in UK using various modalities.35 patients were diagnosed 
with cancer out of which 29 were invasive.45% of these cancers 
were less than a centimeter and 14% had spread to the axilla .the 
sensitivity in the study was 77%for MRI and 40 % for 
mammogram and specificity were 81% and 93% respectively 
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 Warner et al from Toronto screened236 women from 25-65 years 
of age for duration of 3 yrs & identified 22 new cases of which 16 
were invasive using multi-modality. Sensitivity of MRI was 77% 
and 36% for mammogram and specificity were 95% and 99.8% 
respectively 
 
 Kuhl et al at a center in Bonn studied 529 women starting from 30 
and above for duration of 5 yrs. They identified 43 cancers out of 
which 34 were invasive with 1 interval cancer. Nodes were positive 
in 16 % of the study group. The sensitivity of MRI was 91% & 
mammogram was 33%.specificity of both were 97 % 
 
 The International Breast MRI Consortium at 13 centers in the US 
studied 390 women between 25 yrs & above on a single occasion. 
They detected 5 cases of cancer out of which 4 were detected by 
MRI and only 1 by mammogram. However on further evaluation 
the specificity of mammogram was 98%compared to 95% with 
MRI. 
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 Sardanelli et al from Italy screened 278 women at 9 centres aged 
above 25 years .after screening 18 cases were detected with cancer 
out of which 14 were invasive.sensitivity of MRI was 94% 
compared with mammogram for 59%.MRI specificity was 99% 
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THEORY ASPECT: 
Breast cancer is a malignancy arising from the terminal ductal 
lobular units of the breast and hence called ductal and lobular carcinomas 
respectively. 
It is the most common malignancy in women, worldwide. There is 
a decrease in mortality due to early diagnosis,using screening 
mammograms and adjuvant treatment.Earlier detection is still important. 
A small breast tumor usually carries no symptoms and treatable 
when detected early. 
Hence , it becomes a must for women to follow the guidelines for 
screening as per recommendations to detect breast malignancy at its early 
stages. Common symptoms are: a lump in the breast without any pain or a 
lump in the axilla, breast pain, heaviness, skin changes, nipple discharge, 
and erosion. 
The breast is made up of two types of tissues- glands & stroma. 
The former is made up of ducts & lobules. The latter is formed by the fat 
& fibrous tissue that form the skeleton of the breast by giving it its size 
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and shape.The breast contains fat, fibroglandular tissue and neurovascular 
tissue like arteries,veins, nerves and lymph nodes. The fibroglandular 
tissue is further divided as stromal tissue:fibrous connective tissue and 
Cooper’s ligament(also called suspensory ligament) and glandular tissue 
:lobules and ducts. Breast cancer is considered as the abnormal growth of 
glandular tissue of the breast. Breast cancers that are confined to the 
epithelial cell layer that form the lining of the ducts and lobules are 
termed in situ, and generally considered curable by oncologists. Invasive 
carcinoma usually penetrates the basement membrane and invades 
surrounding stromal tissue. These tumor are capable ofmetastasis.1:8 is 
the average lifetime risk of a woman to procure cancer,& breast cancer is 
the 2nd leading cause of cancer mortality among women. The extent of 
spread decides on the survival .the 5 year survival for disease confined to 
the ductal –lobular unit is 98% and for regional disease that is still limited 
to the breast the survival is 84% and 23% for distant metastatic 
disease.hence , early detection of breast cancer is important for the 
management of breast cancer . 
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 The human breast is described anatomically as overlying the 2nd - 
6th rib, & extent: from lateral border of sternum upto the anterior line of 
axilla. Also , a thin layer of breast tissue extends from the clavicle upto to 
the 7th or 8th ribs & from midline to the latissimus dorsi posteriorly.This 
is important in a mastectomy, in which the whole breast has to be 
removed. The axillary tail of the spence has immense surgical 
importance. In some patients it can be palpable & it is considered normal, 
& in some it is seen premenstrually / lactation. A well formed axillary tail 
is often mis-diagnosed as an enlarged lymph nodes / lipoma. 
A lobule is the structural unit of the breast. The number & size of 
the lobules vary among every woman: they are most in number in young 
women. From 10 to over 100 lobules empty into the ducts into a 
lactiferous duct which is 15 to 20 in number. Each duct is lined by 
spirally arrangedmyo-epithelial cells & a terminal ampulla — a reservoir 
for milk or abnormal discharges. 
The Cooper’s ligament are hollow cone like projections of fibrous 
tissue within the breast , the apex of the cones being attached to 
superficial fascia & hence to the skin over the breast. These ligaments 
when involved in a carcinoma cause dimpling. 
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The areola consists of involuntary muscles arranged in 
concentrically as rings & radially in the subcutaneous fat. The areola 
contains many sweat glands & sebaceous glands, the latter enlarge in 
pregnancy & lubricate the nipple while lactation & these are also called 
Montgomery’s tubercles. 
The nipple is overlayed by thick& corrugated skin . the apex 
contains the openings of the ducts. The nipple also made up of 
involuntary muscle fibres seen concentrically & longitudinally; thus is an 
erectile structure which points outwards. Lymphatic drainage of the 
breast is predominantly into the axillary & internal mammary lymph 
nodes. The axillary nodes receive 75 % of the drainage & are present as 
the groups below: 
•lateral:parallel to the axillary vein; 
•anterior: lateral thoracic vessels; 
•posterior: subscapular vessels; 
•central: embedded in the fat at centre of the axilla; 
•interpectoral: nodes in between the pectoralis major & minor muscles; 
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•apical: lie above the level of pectoralis minor tendon ; continuos along 
the lateral nodes & receive the efferents from other groups. 
The apical group of nodes are in continuity with nodes of the 
supraclavicular group & drain into the subclavian lymphatics which 
enters the veins directly or via the thoracic duct or jugular trunk. The 
sentinal node is that lymph node designated as the first axillary node 
draining the breast. 
The internal mammary nodes are fewer in number and lie along the 
internal mammary vessels deep to the plane of the costal cartilages. 
Magnetic Resonance Imaging (MRI) is a powerful & highly useful 
imaging modality that uses non-ionizing radiation by providing a very 
good soft tissue contrast.  
The major composition of the body is water that is composed of 2 
H atoms & 1 oxygen atom. Hydrogen atom is a proton& acts as an 
electric dipole, and in the presence of a large Field of magnetism , the 
protons will come to lie parallel/ antiparallel to the field. However,the net 
magnetization will be along the direction of the main field. In an MRI 
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scan, a short pulse tuned to the Larmor frequency excites a component of 
the magnetization into the transverse plane. 
The tissue’s relaxation properties and the proton density determine 
the received signal, and the imaging gradients allow spatial localization 
of the signal. 
The quality factors in MRI are the signal-to-noise ratio (SNR), the 
presence of imaging artifacts and spatio temporal resolution.the clinical 
applications of MRI include cardiac,renal, vascular,breast, 
musculoskeletal, and brain imaging.High spatio-temporal resolution is 
crucial in dynamic contrast-enhanced(DCE) breast MRI in which 
morphologic and kinetic data are used to arrive at a diagnosis. 
Types of breast cancer: 
Breast cancer has several subtypes .Breast cancer can be divided into 2 
types: 
1. Carcinoma in situ :the malignant mass is confined inside the tissue in 
which it has developed 
11 
 
2. Invasive carcinoma: when the malignant mass invades surrounding 
tissue. 
Histological subtypes: 
1. Invasive ductal carcinoma (IDC). Begins in a duct, then breaks into the 
basement membrane & invades the stromal tissue.(75%) 
2. Ductal carcinoma in situ (DCIS): Cancerous cells develop inside a 
duct, but do not invade the basement membrane. 
3. Invasive lobular carcinoma (ILC): Starts in a lobule gland and invades 
into the surrounding tissue.(10%) 
4. Lobular carcinoma in situ (LCIS): begins in a lobular gland, but does 
not penetrate the basement membrane of the gland’s wall. 
5. Medullary carcinoma: Invasive breast cancer which has a well-defined 
boundary between the cancerous tissue & surrounding tissue.(<10%) 
Less common breast cancer types : 
colloid carcinoma, 
tubular carcinoma & adenoid cystic carcinoma. 
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 Breast Cancer Subtype Markers Expressed 
Type Luminal A   ER &PR,ER/PR positive, low proliferation 
Type Luminal B    ER & PR,ER/PR positive, high proliferation 
HER2 /Neu Positive  HER2/Neu+ve 
Thriple Negative No markers expressed 
 
Modes of spread in breast cancer: 
1.Local spread: The tumour size increases &erodes other portions of the 
breast .i.e the skin /pectoral muscles/ chest wall. 
2.Lymphatic spread: involvement axillary lymph nodes & internal 
mammary chain of lymph nodes. The site of the tumour within the breast 
does not dictate which nodes will be involved, e.g. medial tumours spread 
just as readily to the axillary nodes as do lateral tumours. The 
involvement of lymph nodes is rather a marker for metastasis. In 
advanced disease there may be involvement of supraclavicular nodes and 
of any contralateral lymph nodes. 
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3.hematogenous Spread :metastasis to bone as in the lumbar vertebrae, 
femur,ribs, thoracic vertebrae, & skull; they are osteolytic lesions. Liver, 
lung & brain, the adrenal glands and ovaries may also develop metastasis. 
RISK FACTORS: 
 The first and most important risk factor is being a woman ,the 
incidence ratio being 100:1 
 The next being age 
 Post pubertal weight gain , obesity,hormonal therapies ,alcohol 
consumption are all considered modifiable risk factors 
 High breast tissue density,hyperplasia of breast confirmed by 
biopsy,high bone mineral density and chest irradiation increase the 
risk of breast cancer 
 Nulliparity,age at first child birth being 30 or above ,long 
menstrual history and use of OCPS/HRT 
 Family history of breast cancer and inheritance if BRCA1 /BRCA2 
genes 
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Risk Factors for Breast Cancer in Women (American Cancer 
Society, 2012) Relative Risk Factor: 
 4.0: Age:> 65 years of age upto 80 the risk increases steadily   
Biopsy-proven atypical ductal/lobular hyperplasia   familial 
mutations for breast cancer i.e :BRCA1 & BRCA2   increased breast 
density on mammogram  Personal h/o cancer breast 
 2.1 - 4.0: High levels of endogenous estrogen /testosterone  High 
bone density in elderly post menopausal age group  Irradiation to 
chest wall in high doses  2 1st-degree relatives having a h/o cancer 
breast 
 - 2.0 :Alcoholism 
   Ashkenazi Jew lineage 
             Menarche as early as 12 years of age 
             Tall stature 
             Greater socioeconomic status 
             First full-term pregnancy at >30 years 
              Late menopause at >55 years 
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              H/o not breast feeding child 
              Nulliparity or no full-term pregnancies 
              Obesity  
             One 1st-degree relative with breast cancer 
             Personal h/o endometrial, ovarian, or colonic malignancy 
              Recent use of hormonereplacement therapy postmenopausally                         
estrogen & progestin) 
  Recent use of OCPs 
CLINICAL PRESENTATION: 
 Painless lump, palpated through self-examination or clinical breast 
examination. 
  An abnormal finding on a mammogram or MRI can identify 
cancer even before the lump becomes palpable. 
 nipple abnormalities, skin irritation/ redness/thickening, bloody 
nipple discharge in non  lactating  Women and swelling. 
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 palpable axillary nodal metastases or even metastases to the bone, 
brain or liver, may be the only presenting sign 
 Clinical presentation 
 Upper outer quadrant is the commonest site of breast cancer 
although it may occur anywhere along the breast tissue. They 
commonly present as a hard lump, along with indrawing of the 
nipple. As the disease progresses there will be involvement of the 
skin in the form of peau d’orange / frank ulceration & chest wall 
fixity. This is also known as cancer-en-cuirasse. The locally 
advanced breast cancers present as 5 per cent of breast cancers in 
the developed world and upto 20 per cent in the developing world. 
The patients must be evaluated for staging so that the nature 
&extant of the disease can be ascertained. This will include a 
careful clinical examination, chest X-ray, serum alkaline 
phosphatase and gamma glutamine transaminase (GGT), with liver 
ultrasound if these are abnormal, and an isotope bone scan . This is 
important for both prognosis and treatment — a patient with 
widespread visceral metastases may obtain an increased length and 
quality of survival from systemic hormone or chemotherapy, but 
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she is not likely to benefit from surgery as she will die from her 
metastases before local disease becomes a problem. In contrast, 
patients with relatively small (less than 5 cm in diameter) tumours 
confined to the breast and ipsilateral lymph nodes rarely need 
staging beyond a good clinical examination as the pick-up rate for 
distant metastases is so low. 
 Phenomena resulting from lymphatic obstruction in Staging of 
breast cancer 
 advanced breast cancer 
 Peau d’orange: is due to oedema of the skin. When the skin 
infiltration is tethered due to the sweat glands & their ducts which 
cannot swell, causing an appearance like orange peel. The same 
finding can also be seen in a chronic abscess. 
 Late oedema of arm is a troublesome complication of breast cancer 
treatment fortunately seen less often now that radical axillary 
dissection and radiotherapy are rarely combined. It does however 
occasionally still occur after either modality of treatment alone and 
appears anytime from months to years after treatment. There is 
usually no precipitating cause but recurrent tumour should be 
18 
 
excluded as neoplastic infiltration of the axilla can cause arm 
swelling due to both lymphatic and venous blockage. This 
neoplastic infiltration is often painful due to nerve involvement. 
 An oedematous limb is susceptible to bacterial infections following 
quite minor trauma, and these require vigorous antibiotic treatment. 
Treatment of late oedema is difficult but limb elevation, elastic arm 
stockings and pneumatic compression devices can be useful. 
 Cancer-en-cuirasse:The chest wall is infiltrated with malignancy 
and looks similar to a coat. 
 It is often associated with a grossly swollen arm,and this is seen in 
local recurrence following mastectomy, and occasionally is seen to 
follow the distribution of irradiation to the chest wall. The 
condition may respond to palliative chemotherapy however 
survival is poor. 
 Lymphangiosarcoma is rare complication of lymphoedema with an 
onset many years following the original treatment. It takes the form 
of multiple subcutaneous nodules in the upper limb and must be 
distinguished from recurrent carcinoma of the breast. The 
prognosis is poor but some cases respond to cytotoxic therapy or 
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irradiation. Interscapulothoracic (forequarter) amputation is 
sometimes indicated. 
AJCC Cancer Staging. 7th Edition (AJCC, 2011) 
Tumor size: 
TX : tumor not assesses 
T0 : No primary tumor 
Tis:  
Tis DCIS 
Tis LCIS 
Tis Paget disease of the nipple with no tumor. 
T1 :Tumor <_ 2cm size  
T1mic: Microinvasion < 0.1cm 
T1a :Tumor >0.1 cm but < 0.5 cm  
T1b: Tumor > 0.5 cm < 1.0 cm  
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T1c :Tumor > 1.0 cm < 2.0 cm  
T2 :Tumor >2.0 cm but < 5.0 cm 
T3 :Tumor > 5.0 cm  
T4 :  
T4a : chest wall involved, does nt include pectoral muscle 
T4b: Edema / ulcer of skin / satellite nodules in the same breast 
T4c : T4a and T4b 
T4d: Inflammatory breast carcinoma 
Regional lymph nodes (N) 
NX : nodes not assessed 
N0 :No regional lymph node deposits 
N1 : mobile same side axillary lymph node(s) involved 
N2  
N2a :Metastasis to same side axillary lymph nodes which are matted 
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N2b: involvement of clinically palpable ipsilateral internal mammary 
nodes & no axillary lymph node metastasis 
N3 : 
N3a :same side infraclavicular lymph node involved 
N3b: same side internal mammary lymph node & axillary lymph node 
involved 
N3c :same side supraclavicular lymph node involved 
Pathologic classification (pN) 
pNX: local lymph nodes not assessed 
pN0 :-ve local lymph node metastasis by histology 
pN0(i-): -ve local lymph node metastasis by histology, negative 
immunochemistry 
pN0(i+:) –ve local lymph node metastasis by histology, +ve IHC, & no 
IHC clustering >0.2 mm 
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pN0(mol-) :-ve local lymph node metastasis by histology, & _ve 
molecularity 
Stage 0 (DCIS): Nearly 100% 10-year overall disease-specific survival 
rate. 
Stage I: 90% 10-year overall disease-specific survival rate. 
Stage II: 75% 10-year overall disease-specific survival rate. 
Stage III: 40% 10-year overall disease-specific survival rate. 
US PREVENTIVE TASK FORCE: recommends genetic testing 
for BRCA mutations (American Cancer Society, 2012) for: 
1. Women who are not of Ashkenazi (Eastern European) Jewish 
heritage should undergo 
genetic evaluation if they have any of the following riskfactors: 
• Two first-degree relatives either mother/ sister/ daughter, one of 
whom was diagnosed when 
less than 50. 
• Three or more first- or second-degree relatives (including 
grandmother& aunt) diagnosed 
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with breast cancer. 
• Both breast & ovarian cancer in 1st/2nd degree relatives. 
• A 1st degree relative with cancer in both breasts. 
• 2 or more 1st /2 nd-degree relatives with ovarian cancer 
• A male relative with h/o breast cancer 
2. Ashkenazi women of Eastern Europe must undergo molecular& 
genetic 
studying, if they have: 
• 1st degree relative with history of breast / ovarian cancer. 
•atleast 2 2nd degree relatives in the family with breast / ovarian 
cancer. 
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The ACS guidelines for the early detection of breast cancer: in 
women with average risk & no symptoms:American Cancer Society, 
2012: 
Age 20-39: 
• (CBE) at least once in every 3 years.CBE:clinical breast examination 
• BSE:breast self examination 
Age 40 and over: 
• mammogram annually 
• clinical breast examination annually - prior to a mammogram 
• BSE:breast self examination 
BSE:Breast self-examination must begin as early as 20 years & 
performed every month. The breast is easily examined immediately 
following menstruation. This can be uncomfortable to patients, especially 
inthr presence of fibrocystic change because it will be inconclusive. BSE 
must be 
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learnt early & reinforced regularly. If a palpable tumor develops, women 
who perform BSE present with smaller tumors (1 cm or less) than the 
women who do not perform this technique. Improvement in survival from 
breast cancer has not been demonstrated, however. 
Some women should not practice BSE because of the psychological 
trauma they suffer 
from frequent false-positives. These women need a breast examination by 
the physician once or twice in a year. 
CBE: Clinical breast examination also should begin as early as 20 years 
& done every year for women with moderate risk for breast cancer. 
Tumors <1 cm are difficult to detect excepting experienced clinicians 
whereas tumors >1cm are detected easily. As the tumor grows, 96% of 
tumors larger 
than 2.0 cm can be identified on physician physical examination. Clinical 
breast examination 
must be included in the primary care health system maintenance & 
screening programs. 
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Screening modalities: 
Mammography,CBE: physical examination by at least 2 Early Breast 
Cancer staff & breast self-examination (BSE) are important mass 
screening tools 
 Mammography is proven to reduce the mortality due to breast cancer. A 
medio-lateral oblique-view mammogram alone showed a reduction in 
mortality by 32% in women aged 40–74years. The overall sensitivity is 
91–100% for women aged above 50 & 83% for40–49 year old women. 
Denser breast tissue in young women are a cause of decreased sensitivity 
& the sensitivity can further be increased by a two-view mammogram. 
Single view mammogram was preferred due to minimal radiation dose. 
With latest mammographies the risk is quiet low. A research conducted 
on 1- versus 2-view mammograms have concluded that a second 
additional (craniocaudal) view, the sensitivity increased from 83% to 
89% & 14 new cases were detected out of 217 patients.Recall to the 
hospital was reduced by the second view, (8.8% to 6.6%).hence , by the 
addition of two views is proven to be more accepted& effective & is very 
sensitive as a first screening modality. The effect of using clinical 
examination only is not yet tested.it is usually done in combination with a 
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mammogram. An analysis done in Edinburgh shows that the 63% 
sensitivity for mammograms & 40% for clinical examination . There is no 
proven advantage of breast self-examination, as there is no proven 
evidence of reduction in mortality by this method. The sensitivity appears 
to be low as it is an entirely subjective method. However they can be 
done frequently when compared to a professional clinical breast 
examination .there is also a reduction in the size of the tumor by self-
breast examination as the patient presents earlier to the medical set up. 
Women should be encouraged to practise, as it allows an earlier 
diagnosis.Mammography has a false-negative rate of at least 15%. For a 
breast cancer to bedetected on mammography, it must have tissue 
characteristics that are different from the surrounding tissue. Some 
tumors, particularly lobular carcinoma, invade the surrounding breast 
tissue in a way that does not alter the characteristics of the breast tissue. 
Such tumors are often not visible on mammogram 
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MRI is a newer modality that is proven to have higher sensitivity for the 
purpose of detection of abnormality in the breast. women above the age 
of 50 are the population at greatest risk of cancer breast.Mammography is 
a relatively cheap,& effective & quick mode of screening of the 
breast.MRI is not been used as a mass screening tool. It is very 
expensive,& the equipments & experienced clinicians are unavailable at 
all places these days, &the procedure is takes some time. But MRI is used 
in screening young women ( <50 years) who are at a high risk of 
developing breast cancer. In these groups, the breast will be dense on 
mammogram & they are difficult to conclude. The need to screen women 
at high risk of breast cancer is well recognized,as they can get affected at 
a younger age than the rest of the population and there are always issues 
of repeated radiation exposure. With the invention of newer methods of 
genetic studies, high risk groups can be identified, in which X-ray 
mammograms is nt a good method of screening. MRI tends to avoids 
radiation exposure,along with higher sensitivity in to detect breast cancer, 
also in the dense breast. Annual MRI on comparison with annual 
mammogram in the risk group has shown a higher sensitivity. MRI is 
currently recommended for screening in group of women (25–29) & 
29 
 
those aged 30–50 in those with denser breasts. No screening is currently 
adviced for women less than; women of 30–50 years with denser breasts 
must have annual 2-view mammogram, those over 50 years of age will 
have 3-yearly mammogram. 
Triple assessment: 
Patients with breast lump / symptoms suggestive of carcinoma, the 
diagnosis must be made by clinical assessment, tissue sample taken for 
either cytological or histological analysis & radiological imaging are 
done and this is called triple assessment. 
NEWER IMAGING TECHNIQUES: 
 A film screen mammogram is considered as the well established 
technique for imaging of the breast: screening & diagnostic.this method 
detects about 85% of breast cancers & diagnose these at an earlier stage 
to decrease the mortality by upto 50%. Mammogram is the most common 
imaging technique used all over the world.In a mammogram a beam of 
X-rays traverse the breast & project a image on a film.Newer imaging 
modalities are the requirement of the present 
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Radiologists have a varied ability to read mammograms Mammograms 
have a specificity which is low. The chance that a lesion detected by 
mammogram & Biopsied ,the chance it will turn out to be malignant in 
about 20 to 35%.Densities of tissues are all similar & this causes 
decreased sensitivity. X- radiations can cause DNA damage 
A) MRI Imaging 
 Cancer diagnosis : 
MRI uses magnetic fields as well as radio waves for diagnosis . Patients 
must lie down on a table during the procedure, taking about 30 minutes 
duration. They are moved into the MRI machine, which has a strong field 
of magnetism. An IV contrast material is injected into the patient’s veins 
& the magnetic resonance monitors the way in which the contrast is taken 
up by the tissue & its clearance. In order to identify a mass it must have a 
different appearance from normal tissue. In that case of MRI, the contrast 
between the tissues is 10 to 100 times more than that produced by x-rays . 
MRI can detect malignancies not detected by mammogram. The huge 
disadvantage of MRI of the breast is the cost, 5 times more costlier than a 
X-ray mammogram. 
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 MRI guided biopsy:  
The MR systems consists of a low-field (0.5T) superconducting 
magnet with its configuration in open mode & this allows the 
clinician some access to the interventional field. This machine was 
built for guiding biopsies: imaging will be done during the 
procedure, and the physician selects an image at the 
beginning,during and after the procedure.These machines are still 
experimental,& costly, & few are in use.All over the world. 
B) Digital Imaging 
The detector will absorb the x-rays & modify them into an electrical 
signal &creates the digital image. When images are created there is no 
actual need for a film & the cost and time are saved. 
a) Stereotactic imaging 
Stereotactic breast biopsy: currently commercially available digital 
mammograms. They contain detectors which are very small, & the 
radiologists have the opportunity to identify a lesion discovered by a 
mammogram,& accurately put a needle into the center, & to extract tissue 
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samples. The patient can opt for a least costly, least invasive, & more 
cosmetic procedure when compared a conventional biopsy. 
b) Full field digital mammography: 
it is in the research stages. Digital mammogram is “an evolving 
technology with the greatest potential on management of breast cancer”. 
It provides an image with features of high-resolution& high-contrast with 
the least radiation exposure to the patient. 
c) Single Energy X-ray technique 
it is also called defraction-enhanced imaging (DEI). It produces a much 
clearer,& picture with enhanced details of the breast , & this can improve 
the efficacy of mammogram. This procedure utilizes a single-energy X-
ray source. This technique is also under research, and still more 
researches are needed to be done before it can be used in the community. 
d) 3D digital reconstruction 
This follows the principles of needle biopsies to detect breast cancer. 
Guided biopsies are done using stereotactic biopsy needles& digital 
detectors . The image is very satisfactory, & can generate both 3D /2D 
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images of the breast. This will improve the accuracy of diagnoses using a 
mammogram. 
e) Tomosynthesis: 
 multiple images are obtained using the x-ray tube which is moved as an 
arc over the static breast & digital detector. This method carries the same 
radiation dose toimage the whole breast as that of a single film-
mammogram. Any plane of breast can be brought into a sharp focus.it can 
increase the specificity of mammogram as it reduces the fibroglandular 
tissue that mask the lesion.it is extremely useful in women with dense 
breasts. 
f) Computer-aided diagnosis 
in this method the mammogram and the computer systems are linked. The 
computer automatically draws an area of abnormality, marking the 
suspicious regions. Older methods of pattern recognition & detection of 
microcalcifications in digital mammography. 
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C) Ultrasound Imaging 
a) High frequency Sonography 
Sonograms demonstrate the borders & internal texture, precisely when 
compared to a 
mammogram. They easily identify simple cysts of the breast. They alter 
the degree of suspicion of malignant lesions,& delineate the extent of 
lump in the breast . 
b) Doppler study: 
malignancies of the breast show increased blood flow, which is important 
for metabolism.this method allows to detect normal / abnormal 
vascularity in the mammary gland. This is quiet easy &non invasive.it 
can also assess the blood velocity & volume. 
c) Contrast Imaging 
Ultrasound contrast imaging : in this method a “contrast ”in a 
microbubbled gas form is injected IV. They cause echo-enhancement& so 
in malignancy the signals received are long &great when compared to 
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benign lesions. Malignancies also show changes in morphology of blood 
supply, with neovascularity seen on the lesion. Contrasts improve 
vascular markings. The signal-to-noise ratio is increased , & accuracy of 
diagnosis is alsoincreased. 
d) Sonoelasticity: 
this type of ultrasonogram visualizes the elasticity / stiffness of structures 
as demonstrated by the movement of the tissue to a vibration source.so 
the hard tumors which are usually missed by older ultrasonograms can be 
detected using a sonoelastic technique. 
e) Guided biopsy 
this technique utilizes real-time imaging like a movie & this system 
produces a definitive diagnosis .This can be done in combination with 
mammograms. 
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D) Nuclear Imaging 
a) PET scans: 
in PET scans ,the patient is injected a radiolabelled glucose tracer. Cells 
have increased metabolism, like in case of infection /cancer, will pick up 
more of glucose. The radioactivity of the radiolabeled glucose is studied 
by a PET camera,& the image analysed & regenerated by a system i.e 
areas of hypermetabolism will be bright on the image created& similar to 
a routine CT scan. It is costly & the trcer is not available everywhere PET 
scanning is not commonly performed.it is possible to predict the response 
to systemic therapy in neoadjuvant therapy using PETscan, but methods 
take several months to show results. These scans can also detect 
metastasis to other sites before surgery. 
b) Sestamibi scans: 
Commonly applied radiolabelled tracer in scanning of the breast is Tc-
99m-sestamibi. It is aradioactive isotope, tagged with biological 
molecules, & are injected IV into patients.They reach the area of interest 
& then,a gamma camera is used which converts the emissions into images 
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which detail both the function as well as anatomy of the structure. 
Sestamibi scanning of the breast has only been proven to be effective in 
large breast cancers, & its role in the diagnosis remains unestablished. 
E) BioElectric Imaging: 
This method can detect the tumors at an early stage and pre malignant 
lesions without radiation to the patient. Alterations in the water content & 
properties of the cell membrane of the cell cause changes in the electrical 
impedance of the tissue. The principles of the procedure is similar to an 
USG . This technique is useful in young women (below 50 years of age) 
as they have increased breast tissue density & that will not be effectively 
studied with a traditional mammography. 
F) Optical Diffusion Imaging: 
this imaging method uses infrared rays due to its ability to probe tissue 
oxygenation &metabolism .this method is non invasive & cost effective 
& uses non-ionizing radiation. structures allowing light penetration of the 
laser are those which have a low absorbing window. The conclusion is 
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made with the degree of tissue attenuation at both the wavelengths &this 
can diagnose malignancy. 
American cancer society guidelines suggest including MRI along with 
mammographic screening in women found to be high risk for breast 
cancer. These include: 
 Known cases of BRCA1 AND BRCA 2 mutation 
 Women whose mother/sister/daughter are known carriers of BRCA 
mutations 
 Risk assessment tools that find 20-25% or more chance of breast 
cancer in one’s lifetime for any woman 
 Patients with history of chest wall irradiation between 10-30 years 
of age, for eg: being treated for hodgkin’s disease 
 Women with genetic disorders such as Li-fraumeni /cowden 
syndrome or any first degree relative with the disorder 
         However, MRI of the breast has certain common uses such as: 
 For further evaluation of the lesions detected by a mammogram 
 In case of women with high risk and dense breast tissue in whom a 
routine mammogram need not give adequate information 
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 Women with inaccurate results with mammogram 
 Patients with no clinically palpable lump in women who also have 
a highly suspicious lymph node in the axilla 
 Useful in assessing the size and location of multifocal breast 
malignancy 
 In patients whom treatment options may be decided with help of an 
MRI as to whether to do mastectomy or a conservative 
lumpectomy 
 Breast MRI is known to detect malignancy in the opposite breast as 
women presenting as malignancy in one side usually have a risk of 
10% of procuring cancer in the opposite one 
 Involvement of the chest wall in patients with breast cancer 
 To detect tumor recurrence following a mastectomy or lumpectomy 
 In patients with newly detected inversion of nipple which requires 
evaluation 
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ADVANTAGES OF MRI BREAST: 
 It is a non-invasive imaging modality with does not have any risk 
of exposure to ionizing radiation 
 It is more valuable in breast cancer ,than a mammography 
/ultrasound as it can both detect and stage a malignancy on which 
the other two fail to provide information 
 Contrasts used in MRI studies are less allergic  
 It has growing popularity in detecting early breast cancer 
 Detects small breast lesion that are missed by mammogram 
 Traditional mammograms donot detect lesions in dense breast 
tissue and in breast implants, and MRI is useful in both these 
situations 
 Used as an additional tool along with mammogram in evaluating 
women with high risk of breast cancer 
 In a lesion detected only by MRI ,a guided biopsy can be done 
using MRI. 
 MRI is better in detecting response to chemotherapy than other 
modalities 
 MRI changes the treatment plans in about 15-30% of cases 
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LIMITATIONS: 
 The patient has to lie still for high quality images  
 Obese patients may not fit into the machine 
 Implants and metallic objects hamper the quality of image 
 First trimester of pregnancy-it is usually not advised to undergo 
MR imaging 
 Presence of edema usually affects the result of the study, as MRI 
cannot distinguish malignancy and edematous tissue 
 Obviously, MRI costs more than any other modality 
 Contrast enhanced MR images may pick up benign pathologies 
,which has to be finally decide by the radiologist 
 It has limited availability ,only available in higher centres 
 Tiny calcifications of ductal carcinoma in situ cannot be detected in 
MRI 
 
 
 
42 
 
 
BREAST IMAGING TECHNIQUES: 
The American Cancer Society (ACS) guidelines recommend: 
 Annual x-ray screening mammography for women from age of 40 
and do regular follow up until she is in good health.  
 MRI: first line screening modality for women with a lifetime risk 
as high as 20-25% or greater for breast cancer. Recent studies have 
shown MRI to be more sensitive for this population as compared to 
mammography. 
 Mammography: Low-dose x-ray procedure is the standard 
screening imaging modality for the breast. Tissue contrast in 
mammography is usually the tissue’s absorption of the x-ray as it 
passes through the breast. Cancers on mammography are visualized 
as mass or micro calcification. The sensitivity of mammography 
remains variable. 
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MAMMOGRAM: 
A x-ray modality used to image the breast 
1 screening mammogram:when performed in a woman with no 
symptoms 
2 diagnostic mammogram:. When performed in women with symptoms, 
like a mass/ after an abnormal screening, this includes additional 
magnifying images and often will also include a focused ultrasound.  
        The sole idea of a mammogram for screening is detection of breast 
malignancy. Screening is done in situations of no signs / symptoms, for 
detecting the cancer as soon as possible. A routine mammogram increase 
the chance of a woman being diagnosed with breast cancer at an early 
stage, when it is curable. It is proven that this method can detect cancer in 
2-3 years earlier than it becomes palpable. The American Cancer Society 
(ACS) recommends a yearly screening study for all woman above 40 
years and at moderate risk. Presence of microcalcifications/ other 
abnormalities are commonly associated with cancer. New digital system 
& computer-aided detection(CAD) aid in the mammograms detection of 
tiny calcifications.  
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The greatest risk factor for breast cancer is age. Certain women with a 
family history ofcancer are at a higher risk. Mammography must begin at 
a younger age for them.  
Diagnostic : to study in detail the existing tumori.e.a lump/nipple 
discharge/ focal tenderness .Detailed evaluation of abnormalities detected 
on screening can be studied furhther. The radiologists view 
them&additional views are taken if necessary.An ultrasound is used to 
determine cystic or solid areas ina lesion.PET scans / MRImay be done 
for detailed study of a tumor, but mammograms are very useful 
fordetection of small tumors while screening.  
Procedure: 
A mammogram may be performed in various centres.. Mammography is 
done with machines having x ray beam filters.smaller dtails of the breast 
are visualized using latest equipments  
A woman must fill a questionnaire regarding her medical history, 
personal & family history of cancer, menstruation pattern , previous 
breast surgeries, children use of OCPs, & HRT.  
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A physical examination must be prior to a mammogram & records of 
lump/ nipple discharge,mastalgia are made.Scars must be made a note of.  
Patient must remove her clothing and jewellery and wear hospital gown. 
A metal marker is inserted into the nipple. Thus the nipple will act as a 
reference helping in precise tumor identity and location. 
 Craniocaudal position (CC):the patient is asked to face the machine 
either standing or sitting. One breast is placed at the cassette holder 
by raising is adjusted to level.the mid film will now contain the 
whole breast along with the nipple &head turned to opposite side 
when the film is taken. The chest wall must be relaxed & 
backwards while the breast is pulled forward. The technician will 
hold everything in place &increase the compression between the 
film holder & paddle using a foot pedal adequate breast 
compression means that the skin is tight & the lateral sides firm. 
The picture is taken .this procedure may make the patient 
uncomfortable however being important. Compressed breasts have 
reduced thickness ,creating a uniform density & separating the 
overlying tissues. This provides a good image &low radiation 
exposure. This is again done on the opposite breast.  
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 Mediolateral oblique position (MLO):the patient must lie on her 
side facing the machine. The film holder must be along the 
pectorals muscle,& this varies by the stature of the patient.The 
machine lies in level with the axilla. The arms are placed on the 
cassette holder. The breast tissue is lifted forward & above & a 
good compression is applied. The nipple must lie at its level & the 
other breast is held away. This is done again for the other breast. 
Four x rays, two for a breast, are pictured. A diagnostic 
mammogram may require some more x rays in different positions 
A mammogram is studied by a radiologist . in case of areas of suspicion 
of an abmormality extra films must be taken. A screening mammogram 
takes 15 to 30 minutes& a diagnostic mammogram amy take an hour. 
Mammograms are not costly. A woman can take a mammogram out of 
her own self and does not require a physician’s prescription. 
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Pre procedure steps: 
A mammogram requires compression and that can be painful. 
Mammograms must be done when the breasts are less tender. One / two 
weeks following a menstrual period , as the breasts are tender during 
menstruation. It also helps by reducing the caffeine intake prior to the 
procedure. Women with hormone therapy have mastalgia.Analgesics may 
be prescribed in patients who are anxious .Women must not use any 
perfumes or powder while mammogram. Particles may stick to the film 
&may produce abnormalities. 
 Calcifications: Calcifications are small mineral deposits within the 
breast tissue.they are commonly found in cancer 
. There are 2 types of calcifications: 
1. Macrocalcifications: 
 Coarse calcium deposits arteriosclerosis of vessels, trauma& 
inflammation. They are usually not malignancy and doesnot 
warrant a biopsy. They are common in older women.  
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2. Microcalcifications:  
Tiny particles of calcium in the breast, either solitary /clustered.         
The shape & layout of microcalcifications provide adequate details 
of the lesion &helps to    analyze how likely it is that cancer is 
present. In case ofa suspicious lesion , a biopsy will be needed. 
Masses: 
 Masses, with /without calcifications, may also be seen on mammograms. 
Masses can be cysts –benign /malignant & solid tumors –benign such as 
fibroadenomas,or malignant. Architectural distortion of the breast, skin / 
nipple which require further evaluation. 
Breast Density:  
An additional measure seen on a mammogram is the breast density, 
which is defined as the proportion of fat to connective tissue in a 
women’s breasts.fat is considered non dense and connective tissue is 
considered dense. There are four categories for breast density : 
1. Entirely fat : i.e there is less than 25% stroma 
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2. Scattered fibro-glandular dense tissue: 25 - 50% stroma present in 
breast tissue 
3. Heterogeneous density: 51 - 75% stroma in breast tissue 
4. Extreme density: > 75% stroma in the breast 
Breast Imaging Reporting and Database System by The American 
College of Radiology  
Category Assessment Follow-up Recommendations 
0 
Require more evaluation, Prior Mammograms must be compared or 
newer images needed 
1  
Negative- will only require regular screening mammogram every year for 
women more than 40 years of age  
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2  
Benign –regular screening mammography every year for women above 
40 years 
3  
Probably Benign – follow up in a short time & then evaluation every 6 
months 
4 
Suspicious Abnormality – Biopsy must Be Considered 
4A: low suspicion 
4B: moderate suspicion  
4C: Findings not classic for malignancy 
        Will need biopsy 
5 
High suscpicion for malignancy needing a biopsy 
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6 
 Biopsy-Proven Malignancy  
BREAST MRI: 
The female breast consists of fatty and glandular tissue, which in turn 
contains the lobules for purpose milk production and connected to the 
nipple by the ducts.Malignancy can be missed due to dense breast tissue 
or incorrect positioning of the breast or simply due to a failure to detect 
the abnormality. 
 Dense breast tissues can attenuate x-rays at a comparable rate to cancer, 
making the diagnosis more difficult. Hence mammography is of less use 
and this is most evident in women at younger age &higher risk for 
malignancy, as denser breasts and aggressiveness of the cancer contribute 
to the sub optimal mammogram sensitivity in this group.The latest digital 
mammography systems have shown to screen in dense breast tissue , but 
there is still room for improvement. 
MRI uses magnetic fields for viewing the breast. The primary and 
foremost advantage of a MRI over mammogram is that it features 
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excellent soft tissue contrast that is used in assessing the morphology and 
exact location of lesions. Clinical breast MRI is done by the 
administration of an intravenous contrast that helps to visualize the tumor 
and differentiate between benign and malignant lesions based on 
shortened T1.breast MRI are not included in routine breast evaluation due 
to its high costs and their variable specificity.this low specificity is 
considered due to lack of standardization as well as lack of expertise in 
this field. Breast MRI is also prone to a wide range of imaging artifacts 
like the cardiac motion artifact/ susceptibility-induced artifacts/failure of 
fat suppression that could potentially reduce quality of the image. Breast 
MRI is a rapidly evolving field with growth of experienced practitioners 
and newer innovations in both the hardware and the software. The false-
positive rate of MRI is usually around 5%. 
Role of MRI in Breast Cancer: 
 Breast MRI offers information about many breast conditions that is 
difficult to be obtained by mammography or ultrasound, especially in 
higher risk patients,EG: genetic susceptibility. Breast MRI is also 
frequently performed during the diagnosis of all early breast cancers in 
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order to identify contralateral and additional ipsilateral breast 
involvement. 
Case reports have shown that MRI staging in breast cancer patients leads 
to occult malignant findings in the ipsilateral breast in upto 3.5% and the 
contralateral breast upto 2.9%. The routine preoperative breast MRI 
evaluation following a diagnosis of breast cancer is currently considered 
controversial because the ultimate impact on patient outcome has not yet 
been defined. However , MRI is a very sensitive method of breast 
imaging, with many studies proving that MRI can improve the 
preoperative staging of breast cancer & has now become a popular tool to 
help in surgical planning and for the detection of occult cancers . 
1.8 Limitations of MRI 
•Normal glandular tissue in the proliferative phase of menstrual cycle 
may show certain enhancement. 
• Benign disorders & post irradiation& surgical scars make it difficult to 
differentiate local recurrence & granulation. 
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• it is difficult to differentiate between inflammatory carcinoma and 
mastitis. 
OTHER IMAGING MODALITIES: 
BREAST ULTRASOUND: 
Ultrasound usually transmits high-frequency sound waves to a tissue and 
records the received echoes and transforms them into a video image. 
Ultrasound remains a second-line modality used for differentiating 
palpable lesions, with regards to breast evaluation. Especially ultrasound 
can differentiate a cyst and a solid mass. Especially in women below 30 
years of age, ultrasound is recommended before a mammogram or MRI 
for assessing whether a lesion is a mass or a cyst. It can also be used for 
spatial localization of a clinically palpable tumor while the course of a 
biopsy or aspiration procedure. The disadvantage with the conventional 
ultrasound is that it is highly observer-dependent resulting in inaccurate 
diagnoses in in experienced hands. 
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BREAST MRI: TYPES: 
PULSE SEQUENCES: The American college of radiology usually 
follows a clinical protocol which includes the presence of a T2weighted 
scan and a T1 weighted double contrast enhanced-MRI with 1 pre-
contrast and 2 post contrast images produced using a bilateral breast coil 
An initial T2 weighted scan should be performed before the contrast 
injection primarily to confirm a benign tumor.both the 2D Fast Spin Echo 
(FSE) sequence and the 3D –FSE-Cube (carries advantage of improved 
spatio temporal resolution)are used]this makes the scan time more 
feasible. Alternative breast MRI imaging techniques like diffusion image 
and Perfusion MRI are used to find the differential diagnosis of lesions. 
TEMPORAL VS SPATIAL RESOLUTION: 
Both the spatial and temporal resolution techniques and making a correct 
choice of these parameters has a strong impact on the diagnostic 
accuracy. There are conflicting reports on the benefits of high 
spatiotemporal resolution on DCE-MRI; two groups show diagnostic 
benefit of increasing spatial resolution but no significant loss in 
diagnostic accuracy with decreased temporal resolution. Certain, other 
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studies claim that a good combination of high temporal and high spatial 
resolution may lead to improved diagnostic accuracy. 
There is no standard protocol for breast MRI and the choice of imaging 
parameters is highly dependent on the institution and the radiologist. It is 
recommended to perform bilateral imaging as the contralateral breast is 
useful for comparison, and also used to detect pathology may also be 
found in the contralateral breast. Imaging of both the breast is usually 
performed in the axial plane due to the ability to cover both breasts in a 
reasonable number of slices when compared to sagittal imaging and good 
visualization of the nipple when compared to coronal imaging. Fat must 
be removed from the image for a clear visualization of the lesions, but  
there are conflicts whether to actively suppress the fat or to exclude it by 
using subtraction. Fat suppression is significantly much better than 
subtraction . 
 The number of phases for DCE-MRI should be adequate to detect the 
initial enhancement and also the subsequent later enhancement, and it is 
important to use a routine or regular receiver settings for all phases. 
Further, alternative and newer breast MRI techniques such as Diffusion 
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Weighted Imaging and Perfusion MRI can aid in the differential 
diagnosis of lesions. 
People in support of subtraction argue that it requires no additional 
scanning time, and its performance is also relatively immune to the field 
in homogeneities however certain group of clinicians are in favour of 
suppression as fat acts as an anatomical reference. 
HARDWARE USED IN BREAST MRI: 
It is recommended to use a good, bilateral breast coil,and recent advances 
facilitate parallel imaging. Bilateral imaging of the breast enables 
comparison with the opposite breast which will be useful at 
diagnosis.continous imaging of both breasts with better use of the IV 
contrast agent and it helps avoid diagnostic errors in patients with non-
masslike enhancement or enhancing foci detected in non contrast 
films.Breast imaging at 3T has the benefit of higher SNR, but at the 
expense of B0 andB+.The image in one breast appears to have higher 
intensity than the other breast, and these are considered in homogeneities. 
The T1-weighted image can vary from side to side, and so the conspicuity 
of lesions on T1-weighted images usually varies. Depending on the fat 
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suppression used, these in homogeneities may result in fat suppression 
failures in some regions.  
CRITERIA FOR DIFFERENTIAL DIAGNOSIS: 
Differential diagnosis of breast lesions on MRI are done based on 
 assessment of the morphology of the lesion- including the 
size,enhancement type ,shape and margins of the mass,distribution 
of the enhancement and internal architecture. 
 Enhancement kinetics & the lesion intensity on T1W and T2W 
scans. 
  High spatial resolution imaging has the ability to detect kinetic 
information ,initial enhancement ,presence or lack of peak 
enhancement and the delayed enhancement patterns. 
 
The radiologist will assess the enhancement kinetics qualitatively by 
reading through sections and time points, this hugely depends on the 
experience on the radiologist. There are certain quantitative methods of 
assessing the enhancement kinetics such as measuring mean signal of 
ROI or using computer aided detection, much better than results obtained 
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by radiologists.the pre –contrast T1wighted image establishes a 
baseline,T2weighted image is used to confirm the benign diagnosis. 
BI-RADS OF MRI: 
The MRI BI-RADS system describes enhancing lesions : 
A focus :enhancing area < 5 mm which is difficult to be further 
described,these are usually not harmful unless there is a rapid increase in 
size.the risk of malignancy increases with the size of the lesion. Thus, any 
foci needs to be monitored carefully to assess the growth of the lesion and 
changes in the nature of  enhancement morphology. 
 
 
   little bright objects detected as foci in MRI 
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 A mass: space-occupying tumor which has three dimensions and 
correlates with both T1W and T2W scans. The D/D of a mass 
maybe invasive breast cancer / benign solid tumor, and detailed 
analysis of the shape and margin of the mass. 
 
     MRI film showing a fibroadenoma 
 
 
  MRI showing speculated margins suggestive of invasive 
carcinoma 
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  A non-mass-like enhancement: Enhancing fibroglandular tissue 
without a detectable three-dimensional mass. The D/D of this could 
be intraductal invasive cancer, mastopathy, hormonal stimulation 
or inflammatory changes. The distribution of the enhancement field 
(whether located along the ductal lining or not) & the symmetry of 
the enhancement are valuable . 
  For eg: bilateral asymmetry in non-mass-like enhancement is more often 
considered to be due to benign lesions   
Distribution pattern of a non mass enhancement is as follows: 
 Focal: less than 25% of a quadrant 
 Ductal : carries a 60% risk of cancer 
 Linear :not oriented with the duct,carries 31% risk of cancer 
 Segmental:occurs along multiple ducts and carries 78%risk of 
malignancy 
 Regional: non ductal /non segmental ,carries 21% cancer risk 
 Diffuse 
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T1-T2 CHARECTERISTICS: 
A pre-contrast T1image without any fat suppression will show fat on a 
lesion. A signal on a T1W can be observed in intramammary 
lymphadenopathy/traumatic fat necrosis. Hamartomas also show high 
signals on T1 images .Fat containing lesion are usually not malignant but 
suspicion must arise if the tumor is rapidly growing, and biopsy must be 
taken. 
In T2 weighted images, look for the presence of fluid. Cysts, lymph 
nodes & fat necrosis show a high signal on T2 images.Colloid carcinoma 
is the only malignancy that produces a high signal intensity on T2 
images.There is a general rule: all lesions with high signal on T2 fat-
suppressed images are benign & non malignant.  
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 T2W IMAGE SHOWING FIBROADENOMA ON LEFT & COLLOID 
CARCINOMA ON THE RIGHT 
Moderate signal intensity in T2 weighted images are: usually malignant 
 invasive lobular carcinoma 
 DCIS 
 Fibrocystic breast disease 
Low signal intensities are seen in: 
 Invasive ductal carcinoma 
 Sclerotic fibroadenoma 
 scar 
Enhancement pattern of a mass: 
There are six patterns of mass enhancement:  
1. Homogeneous :uniform & confluent enhancement thro’out the 
mass. 
2. Heterogeneous: Irregular enhancement, that varies inside the mass. 
3. Rim enhancement: involving the periphery of the mass. This is a 
feature of ductal cancer, traumatic fat necrosis, & benign cysts. 
Rim enhancement in non cyst like lesions run a 40% risk of cancer. 
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4. Dark internal septations :i.e: an enhancing mass with non-
enhancing septations. Eg: fibroadenomas,irregular margins. 
5. Enhancing internal septations:suggestive of malignancy. 
6. Central enhancement:An enhancing mass along the center of the 
mass. Commonly associated with high-grade ductal cancer. 
 
Invasive lobular carcinoma with heterogenous enhancement 
 
Invasive ductal carcinoma with rim enhancement 
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MRI –BIRADS CLASSIFICATION CATEGORY: 
Category 0 Incomplete: requires further imaging evaluation 
Category 1 -ve 
Category 2 Benign  
Category 3 Probably benign  
Category 4 Suspicion of malignancy 
Category 5 Highly suggestive of malignancy 
Category 6 Proven cancer 
BREAST MRI –DIAGNOSTIC INTERPRETATION: 
Both morphological and kinetic data are assessed in a breast MRI. The 
kinetic data usually contains 2 fragments: initial enhancement and 
delayed enhancement. In the lesion morphology: size, shape and margins 
(boundaries) become important criteria for diagnosis.  
 Normal fibroglandular tissue has variable enhancement;with no 
early phase enhancement and it persists in later phases . 
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 Invasive cancers : Focal masses with irregular shape and irregular 
or spiculated margin, and they show washout with heterogeneous 
internal architecture or rim enhancement. A spiculated mass is 
alump with spikes-needle-like protrusions on the surface. Invasive 
cancers are hypointense relative to the fibroglandular tissue in 
T2weighted images 
 Fibroadenoma: benign focal masses with round or oval shape with 
smooth margins. The enhancement persists but they can also 
display a washout or plateau, and can have a homogeneous internal 
architecture with by dark septations they can be hypo intense or 
hetero intense in T2 weighted image 
 Ductal Carcinoma In Situ (DCIS): potential precursor to invasive 
cancer. It is usually difficult to diagnose due to unreliable 
enhancement kinetics. DCIS shows asymmetric no mass-like 
enhancement with hetero genity and periductal enhancement. 
Benign mastopathies are the most important differential diagnosis 
with regard to DCIS. As with DCIS, mastopathic lesions present 
themselves as enhancing foci or area of non-mass-like 
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enhancement but when compared to DCIS, they are bilaterally 
symmetric and do not follow the ductal system. 
MRI –CLINICAL APPLICATIONS: 
MRI of the breast is a modality applicable in several areas of the clinical 
management of breast disease due to its versatility. Breast MRI’s role in 
screening for breast cancer can be segmented into two primary causes:  
1. first line modality for screening women with high risk  
2. second line modality for detailed studying of inconclusive findings.  
3. After making a diagnosis of invasive cancer, breast MRI can be 
used in staging the disease& the axillary lymph nodes. 
4. It can be used in monitoring a patient’s response during or after 
neoadjuvant chemotherapy.  
5. After mastectomy, the patient will often opt for breast implants, 
and MRI can detect tumor recurrences in these special cases. 
Clinical Reports and data show high sensitivity of breast MRI, but its 
specificity has been variable in diagnosing invasive breast cancer. This 
variable specificity led to certain inconclusive/unnecessary 
biopsies,amplified by its cost efficacy and inexperience of the 
radiologists. 
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However, as radiologists experience with breast MRI began to increase 
and by the incorporation of lesion morphology in the diagnostic pathway, 
breast MRI is now accepted in clinical practice. It is the first-line 
screening modality for patients with a high risk of cancer in lifetime. 
Recent studies give a much higher specificity for breast MRI (77-100%) 
as compared to x-ray mammogram about25-40% for the same high risk 
group 
RECENT ADVANCESINBREAST MRI: 
CELLULAR MRI: 
It is an imaging technique which incorporates high resolution MRI & 
cells labeled 
With contrast agents to visualize the location of these tumors and 
behavior of these cells in vivo. The following sections give a brief 
description of basic MRI principles, pulse sequences, contrast agents and 
the principles and applications of cellular MRI. 
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Nuclear Magnetic Resonance (NMR): 
Magnetic resonance imaging can be accomplished due to the intrinsic 
property of subatomic particles called spin /the intrinsic angular 
momentum of the particle. All protons, neutrons & electrons have a non-
zero value of spin. Both the proton & neutron have spin equal to a half. In 
nuclei with multiple protons & neutrons, the spin of the entire nucleus 
will be a sum of the spins from all unpaired protons & neutrons. Nuclei 
with a non-zero spin will have a magnetic dipole & have a magnetic 
moment. When a proton, having a spin of ½, is exposed to a magnetic 
field, it will experience a force that causes it to align with the field. But , 
the proton will not align completely & will precess about an axis that is 
parallel to the applied field. The frequency of the proton’s precession / 
Larmor frequency, ωo, in an external magnetic field, B0, is givenby the 
following equation.Where γ is the gyromagnetic ratio, which is 42.57 
MHz/T for a proton. When a volume containing many protons are 
brought under an external magnetic field, as in the case of MRI, a net 
magnetization is produced within the volume that aligns with the 
magnetic field. In the volume, not all the protons will precess in a 
direction that will constructively add to the net magnetization, but will 
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precess in a way that will reduce the size of the magnetization available 
to imaging. This is dependent on both the magnetic field strength & the 
temperature of the volume studied. The magnitude of the net 
magnetization. When an MRI image is acquired, an oscillating magnetic 
field, B1, is applied to the volume in addition to B0, exciting the protons. 
This causes magnetization to tip from the z-axis, which is parallel to B0, 
into the transverse plane perpendicular to B0.The magnetization will then 
gradually return to its original orientation parallel to the z-axis once B1 
has been switched off. The signal measured by the imaging system during 
acquisition is the relaxation of the magnetization back to the equilibrium 
state. During the acquisition process, a series of magnetic field gradients 
in different spatial directions are applied to encode different frequencies 
and phases to different areas of the volume, allowing for the location of 
specific signals to be determined. The signal is detected due to the 
precession of the magnetization in the transverse plane. This induces a 
varying voltage & current in a coil that is placed nearby for detection. 
The magnetization acts as a function of time in the z-axis & transverse 
plane .Where T1 and T2 are relaxation time constants that describe how 
the magnetization within a volume will return to equilibrium. These 
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constants are known as spin-lattice & spin-spin relaxation, respectively,& 
vary between tissues.The process of relaxation involves two different 
mechanisms: T1 relaxation and T2 relaxation. These mechanisms are 
extremely important in determining image contrast & affect the choice of 
pulse sequence used for imaging. The relaxation constants vary between 
tissues & will also change in the presence of disease. 
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AIM OF THE STUDY: 
• To evaluate patients presenting with a breast lump and to evaluate 
them with clinical examination ,cytology and with MRI and 
interpret its findings- with regards to involvement of the opposite 
breast and axilla and level of infiltration and the sensitivity of the 
modality itself. 
• To establish that MRI breast can be made as a routine investigating 
modality in the management of breast cancer by comparing it with 
mammogram  
• To use MRI in detecting local site recurrences in patients with post 
MRM status presenting with pain /ulcers/nodules. 
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MATERIALS AND METHODS: 
ELIGIBILITY: 
INCLUSION CRITERIA:  
Women presenting with breast lump with a cytological evidence of breast 
cancer, both premenopausal and postmenopausal and any stage at 
presentation.  
Women who present post operatively(post MRM)with features of 
recurrence  
STUDY TYPE: Observational 
SAMPLE SIZE: 50 
METHODS: 
Patients who present with complaints of breast lump to the OPD,were 
clinically examined and subjected to cytology & proved to be carcinoma 
and further evaluate them with mammogram and MR imaging of both 
breasts and the results were interpreted with the following criteria: 
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 Size of the tumor 
 Location of the tumor 
 Infiltration to underlying structures 
 Multicentric lesions 
 Involvement of opposite breast and axilla 
 Perform MRI for patients post MRM status presenting with 
operative scar pain/ ulcers/nodules 
These results were compared with those of mammogram performed 
in the same group of patients.  
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OBSERVATION AND RESULTS: 
 OBSERVATION AND RESULTS 
A Total Of 50 Cases Of Proven Ca Breast Were Studied by both 
Mammographic And Mri Evaluation . Of The 50 Cases 47 cases were 
predicted by mammogram and 48 cases were predicted byMRI to be a 
case of breast carcinoma.  
 
 
 
 
 
 
 
 
 
76 
 
MAMMOGRAM VS MRI BREAST 
 
The results were not statistically significant as the p-value calculated by 
chi square test was0.94143 (when p<0.01 is considered significant). It is 
observed that MRI is as good as mammogram in the evaluation of a case 
of carcinoma breast .  
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BIRADS grading 
BI-RADS is an acronym for Breast Imaging-Reporting and Data System, 
a quality assurance tool originally designed for use with mammography. . 
This allows for concise and unambiguous understanding of patient 
records among doctors . 
Of the 50 cases subjected to mammographic evaluation, 22 were under 
BIRADS 4 , 19 under BIRADS 5 and 6 under BIRADS 6  
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BIRADS: 
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STAGING: 
 
OF THE 50 PATIENTS 21 WERE IN STAGE 2A WITH AN 
INCIDENCE OF 42 % , 17 WERE IN STAGE 2B WITH AN 
INCIDENCE OF 34% AND 12 WERE IN STAGE 3A WITH AN 
INCIDENCE OF 24 %. 
Breast cancer staging using the TNM system is based on the size of the 
tumor (T), whether or not the tumor has spread to the lymph nodes (N) in 
the armpits, and whether the tumor has metastasized (M) (i.e. spread to a 
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more distant part of the body). Larger size, nodal spread, and metastasis 
have a larger stage number and a worse prognosis. 
STAGING: 
 
STAGE: 2A: 42% 
STAGE :2B :34%     
STAGE 3A:24% 
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AGE DISTRIBUTION 
The older you are, the higher your absolute risk of breast cancer. Many 
women are more interested in the risk of being diagnosed with breast 
cancer at specific ages or over specific time periods than in the risk of 
being diagnosed at some point during their lifetime. 
 
WOMEN FROM AGE GROUP 20-30 YEARS OF AGE : 6 
WOMEN FORM AGE GROUP 30-40 YEARS OF AGE: 13 
WOMEN FROM AGE GROUP 40-50 YEARS OF AGE: 19 
WOMEN FROM AGE GROUP 50-60 YEARS OF AGE:7 
WOMEN ABOVE THE AGE 60 YEARS OF AGE: 5 
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The strongest risk factor for breast cancer is age. A woman’s risk of 
developing this disease increases as she gets older. The risk of breast 
cancer, however, is not the same for all women in a given age group. 
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Of the 50 cases , 12 % is in the age group of 20-30 
   26 % is in the age group of 30-40 
   38 % is in the age group of 40-50 
   14 % is in the age group of 50-60 
   10 % is in the age group of >69 
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HISTOLOGICAL TYPES 
 
OUT OF THE 50 CASES , INVASIVE DUCTAL CA WAS SEEN IN 26 
PATIENTS , DCIS IN 22 PATIENTS , MUCINOUS CARCINOMA 
WAS SEEN IN 1 PATIENTS AND PAGET’S DISEASE WITH DCIS 
IN 1 PATIENT 
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NODAL INVOLVEMENT: 
 
OF THE 50 CASES STUDIED , 26 CASES WERE NODE POSITIVE 
WHILE 24 WERE MODE NEGATIVE. 
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POST MRM PRESENTATIONS: 
10 CASES OF POST MRM STATUS WERE STUDIED. OF WHICH 7 
PATIENT PRESENTED WITH PAIN , 3 CASES PRESENTED WITH 
ULCER , 4 CASES PRESENTED WITH A NODULE , 2 CASES 
PRESENTED WITH LYMPHEDEMA AND OUT OF THE 10 CASES 
RECURRENCE WAS FOUND IN 4 CASES BOTH BY TISSUE 
DIAGNOSIS AND BY MRI 
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                                               ULCER 
 
 
Patients presenting with ulcer:3 
Pateints with recurrence among the ulcers: 2 
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                                             NODULES 
 
 
Patient spresenting with nodules were 4 out of which 3 were recurrent. 
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                                              PAIN 
 
 
 
Out of 7 pateints presenting with pain 2 cases were proved recuurent. 
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2 CASES OF THE 10 CASES OF STATUS POST MRM , PRESENTED 
WITH LYMPHEDEMA OF THE INVOLVED ARM , WITH AN 
INCIDENCE OF 20 %.  
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DISCUSSION: 
Conventional mammogram is incorporated routinely in both screening 
and diagnostic modalities of investigations of the breast. Mammogram is 
considered as a very reliable method for screening in the case of breast 
carcinoma. 
In this study 50 patients who presented to the surgical OPD were 
evaluated with their consent. History taking, physical examination 
followed by imaging were done systematically. All the patients 
underwent both mammogram and MRI ,and their results analysed. 
Out of the total 50 Cases Of Proven Carcinoma breast Were Studied by 
both Mammographic And MRI Evaluation . Of The 50 Cases 47 cases 
were predicted by mammogram and 48 cases were predicted byMRI to be 
a case of breast carcinoma.  
Out of the50 patients 21 had a stage 2A disease(42%) , 17 had STAGE 
2B disease(34%)and 12 had STAGE 3A(24%). 
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In BIRADS grading of the breast using a mammogram 19/50 patients had 
a BIRADS 5 lesion ,22/50 had BIRADS4,6/50 had BIRADS 6,2 /50 had 
BIRADS 2 & only 1 patient had BIRADS 3. 
Age is the highest known risk factor for carcinoma breast and in this 
study out of 50 patients who presented 6 belonged to 20-30 yrs .i.e: 12% 
incidence,13 patients belonged to 30-40 yrs(26%),19 belonged to 40-50 
yrs(38%) and 7 belonged to above 50 age group(14%) 
Out of the 50 patients 26 had invasive ductal carcinoma,22 patients had 
ductal carcinoma in situ in atypical hyperplasia background,1 patient had 
mucinous carcinoma and 1 patient had paget’s disease of the nipple . 
Among the 50 patients 26 cases had lymph node positive disease and 24 
were lymph node negative. 
48 patients in this study underwent only modified radical mastectomy 
either before or after chemotherapy, and were on regular follow up.2 of 
them underwent palliative chemoradiation. 
Out of these patients 10 had complaints of pain,ulcer,nodules and 
lymphedema.7 patients had pain ,4 presented with a nodule,3 cases with 
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an ulcer and 2 cases with lymphedema and out of them 4 had a recurrence 
proven with the aids of MRI and biopsy. 
On more detailed analysis,2 out of 7 patients with pain had recurrence.3 
out of 4 patients with nodule were recurrent,2 out of 3 patients with ulcer 
had recurrence. 2 out of 10 cases with lymphedema however did not turn 
out to be recurrence by further investigations. 
With regard to MRI as seen in the master chart showed additional 
features of involvement of the pectoral muscles in 6 cases ,and also 
detected opposite breast involvement in 2 cases .these cases underwent 
only palliative chemotherapy. 
LIMITATIONS OF THE STUDY: 
The major limitation of the study was cost factor which was overcome by 
the insurance scheme covered for these patients, and also recent advances 
are not available in the institution like the guided biopsy techniques that 
could have been used and analyzed. 4 out of the 50 patients developed 
claustrophobia that required sedation.  
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CONCLUSION: 
To conclude, in this study both MRI and mammogram detected almost 
equal number of cases ,and the results obtained were not statistically 
significant.in this group both the modalities were of equal efficacy in 
diagnosing cancer of the breast.in addition MRI could also give valuable 
information regarding the level of infiltration and involvement of 
opposite breast and axilla ,that helped in appropriate staging and 
induction of neo-adjuvant /palliative chemotherapy. 
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SUMMARY: 
In this sample size of patients ,the p value did not turn out 
significant(0.94143) and hence the comparison was not statistically 
significant .However, recent studies conducted in a larger population 
have shown that MRI has a better tumour predictability by terms of 
sensitivity when compared to a mammogram.hence MRI scanning of the 
breast can be included in both screening and diagnosis for breast cancer 
in institutions where available , as it has various advantages over a 
mammogram like less radiation exposure ,use in younger age group, 
ability to add on level of infiltration and involvement of opposite breast 
and axilla.this one modality can guide the surgeon in deciding the 
treatment option in patients presenting afresh and post surgical patients  
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marbaga 
ÍÂ ´ôÒ¾ø ÀÊÅõ 
¦ÀÂ÷:    ÅÂÐ:    ¯ûÇ¢ÕôÒ ±ñ: 
 þ ó¾ Á Õ ò Ð Å  ¬  ö Å ¢ý  Å ¢Å Ã í ¸ û  ± É ì Ì Å¢ Ç ì ¸ 
ô À ð ¼ Ð. ± ý Û ¨ ¼Â ºó§¾¸í ¸ ¨ Ç ì §¸ð¸×õ ¾Ìó¾  Å¢ Ç ì¸ 
í ¸ ¨ Ç ô ¦ÀÈ×õ Å¡öôÀ Ç ¢ì¸ôÀð¼Ð. 
 ¿¡ý þùÅ¡öÅ¢ø ¾ýÉ¢î¨ºÂ¡¸ò  ¾¡ý Àí§¸ü¸¢§Èý. ±ó¾ 
¸¡Ã½ò¾¢É¡Öõ, ±ó¾ ¸ð¼ò¾¢Öõ, ±ó¾ ºð¼ º¢ì¸ÖìÌõ ¯ðÀ¼¡Áø 
þó¾ ¬öÅ¢Ä¢ÕóÐ Å¢Ä¸¢ì ¦¸¡ûÇÄ¡õ ±ýÚõ «È¢óÐì¦¸¡ñ§¼ý. 
 ¿¡ý ¬öÅ¢Ä¢ÕóÐ Å¢Ä¸¢ì ¦¸¡ñ¼¡Öõ ¬öÅ¡Ç÷ ±ýÛ¨¼Â 
ÁÕóÐÅ «È¢ì¨¸¸¨Çô À¡÷ôÀ¾ü§¸¡ «øÄÐ ¯À§Â¡¸¢ì¸§Å¡ ±ý 
«ÛÁ¾¢ §¾¨ÅÂ¢ø¨Ä ±É «È¢óÐ ¦¸¡û¸¢§Èý. ±ý¨Éô ÀüÈ¢Â 
¾¸Åø¸û Ã¸º¢ÂÁ¡¸ô À¡Ð¸¡ì¸ôÀÎõ ±ýÀ¨¾ «È¢§Åý. 
 þó¾ ¬öÅ¢ý ãÄõ ¸¢¨¼ìÌõ ¾¸Åø¸¨ÇÔõ À¡¢§º¡¾¨É 
ÓÊ×¸¨ÇÔõ ¬öÅ¡Ç÷ «Å÷ Å¢ÕôÀò¾¢ü§¸üÀ ±ùÅ¢¾Á¡¸ô 
ÀÂýÀÎò¾¢ì ¦¸¡ûÇ×õ «¨¾ À¢ÃÍ¡¢ì¸×õ ±ý ÓØÁÉÐ¼ý 
ºõÁ¾¢ì¸¢§Èý. 
 þó¾ ¬öÅ¢ø ÀíÌ ¦¸¡ûÇ ´ôÒì ¦¸¡û¸¢§Èý. ±ÉìÌ 
¦¸¡Îì¸ôÀð¼ «È¢×¨Ã¸Ç¢ýÀÊ ¿¼óÐì ¦¸¡ûÅÐ¼ý ¬öÅ¡ÇÕìÌ 
¯ñ¨ÁÔ¼ý þÕô§Àý ±ýÚõ ¯Ú¾¢ÂÇ¢ì¸¢§Èý. ±ý ¯¼ø ¿Äõ 
À¡¾¢ì¸ôÀð¼¡§Ä¡ «øÄÐ ±¾¢÷À¡Ã¡¾ ÅÆì¸ò¾¢üÌ Á¡È¡É §¿¡öìÌÈ¢ 
¦¾ýÀð¼¡§Ä¡ ¯¼§É «¨¾ ¦¾¡¢Å¢ô§Àý ±É ¯Ú¾¢ ÜÚ¸¢§Èý.  
 þó¾ ¬öÅ¢ø ±ÉìÌ ±ùÅ¢¾ ÁüÚõ «¨ÉòÐô 
À¡¢§º¡¾¨É¸¨ÇÔõ º¢¸¢î¨º¸¨ÇÔõ §Áü¦¸¡ûÇ ¿¡ý ÓØÁÉÐ¼ý 
ºõÁ¾¢ì¸¢§Èý. 
    þôÀÊìÌ  
¬öÅ¡Ç÷ ¨¸¦Â¡ôÀõ    §¿¡Â¡Ç¢Â¢ý ¨¸¦Â¡ôÀõ    
¼¡ì¼÷.¯.¬.§†õ¿¡ò    (¦ÀÂ÷)     
 
 
 
ÅÂ¢üÚ ÅÄ¢, Ì¼ø ÀÆì¸ Á¡üÈõ ÁüÚõ þÃò¾ô§À¡ìÌ 
¯ûÇ §¿¡Â¡Ç¢¸ÙìÌ ¦ÀÕíÌ¼ø «¸§¿¡ì¸¢Â¢ý §¿¡ö 
¸ñ¼È¢Ôõ Á¸Ý¨Ä ¸ñ¼È¢Ôõ ¬ö×  
¬öÅ¡Ç÷ : ¼¡ì¼÷. ¯.¬.§†õ¿¡ò 
   ÓÐ¿¢¨Ä Àð¼ §ÁüÀÊôÒ Á¡½Å÷ 
   «Ú¨Å º¢¸¢î¨º Àð¼ôÀÊôÒ  
 
Àí§¸üÀ¡Ç¡¢ý ¾¸Åø ÀÊÅõ  
 
 ¿£í¸û þó¾ ¬öÅ¢ø Àí§¸ü¸ «¨Æì¸ôÀÎ¸¢È£÷¸û. þó¾ 
¬öÅ¢ø Àí§¸üÌõ ÓýÉ÷, þ¾ý §¿¡ì¸ò¨¾Ôõ, Ó¨È¸¨ÇÔõ 
þ¾É¡ø ²üÀ¼ìÜÊÂ À¢ýÅ¢¨Ç×¸¨ÇÔõ, ²§¾¨ÉÔõ «È¢óÐì 
¦¸¡ûÇ ¬öÅ¡Ç÷ «Ç¢ìÌõ ¾¸Åø À¢ýÅÕÁ¡Ú 
 
 ¾í¸ÙìÌ ÅÂ¢üÚÅÄ¢, þÃò¾ô§À¡ìÌ ÁüÚõ Ì¼ø ÀÆì¸ Á¡üÈõ 
§À¡ýÈ¨Å þÕôÀ¾¡ø «¾üÌ¡¢Â ¸¡Ã½í¸¨Çì ¸ñ¼È¢Â 
¬ºÉÅ¡Â¢Ûû ÌÆ¡ö ¦ºÖòÐõ À¡¢§º¡¾¨É (¦¸¡Ä§É¡Š§¸¡À¢) 
¦ºöÂôÀÎõ. þ¾ý ãÄõ §¿¡¨Âì ¸ñ¼È¢óÐ «¾üÌ¡¢Â º¢¸¢î¨º 
«Ç¢ì¸ þó¾ À¡¢§º¡¾¨É ÀÂýÀÎõ ±ýÀ¨¾ ¦¾¡¢Å¢òÐ ¦¸¡û¸¢§Èý. 
 
 ¾¡í¸û þó¾ ¬öÅ¢üÌ ºõÁ¾õ ¦¾¡¢Å¢ìÌõ Àðºò¾¢ø þó¾ 
ÀÊÅò¨¾ ÓØ¨ÁÂ¡¸ ÀÊòÐ À¡÷òÐ ÓØÁÉÐ¼ý ¨¸¦Â¡ôÀÁ¢ÎÁ¡Ú 
§¸ðÎì ¦¸¡û¸¢§Èý. §ÁÖõ þó¾ ¬öÅ¢É¡ø ¾í¸û ¯¼Öì§¸¡, 
ÁÉÐì§¸¡, ±ó¾Å¢¾ ¯¨Çîºø ²üÀ¼¡Ð ±ýÚõ ¯Ú¾¢ÂÇ¢ì¸¢§Èý. 
 
 þó¾ ¬öÅ¢ý ÓÊ×¸û ÁÕòÐÅì ¸¡Ã½í¸Ùì¸¡¸×õ 
ÁÕòÐÅì ¸øÅ¢ì¸¡¸×õ ÀÂýÀÎò¾ôÀÎõ. þó¾ ¬ö× ÀüÈ¢Â 
ºó§¾¸í¸ÙìÌ ¯¡¢Â Ó¨ÈÂ¢ø Å¢Çì¸õ «Ç¢ì¸ôÀðÎ, 
¾í¸¨ÇôÀüÈ¢Â  ¾¸Åø¸û þÃ¸º¢ÂÁ¡¸ À¡Ð¸¡ì¸ôÀÎõ. 
 
 þó¾ ¬öÅ¢Ä¢ÕóÐ ±ô¦À¡ØÐ §ÅñÎÁ¡É¡Öõ ¾¡í¸û ±ùÅ¢¾ 
ÓýÉÈ¢Å¢ôÀ¢ýÈ¢Ôõ, ±ùÅ¢¾ ºð¼ º¢ì¸Öõ þýÈ¢Ôõ Å¢Ä¸¢ì 
¦¸¡ûÇÄ¡õ. 
 
þó¾ ¬öÅ¢ø Àí§¸üÌÁ¡Ú §¸ðÎì ¦¸¡û¸¢§Èý. 
  ¿ýÈ¢  
 
 
¬öÅ¡Ç÷ ¨¸¦Â¡ôÀõ    §¿¡Â¡Ç¢Â¢ý ¨¸¦Â¡ôÀõ 
¼¡ì¼÷.¯.¬.§†õ¿¡ò          ¦ÀÂ÷: 
WORKSHEET: 
NAME: 
AGE:                                       SEX:                              IP NO: 
DIAGNOSIS: 
CLINICAL DETAILS: 
 
 
FNAC/BIPOSY REPORT: 
 
MAMMOGRAM: 
 
MRI BREAST: 
 
OUTCOME: 
 
POST MRM PATIENTS: 
1. Complaints: 
2. Presentation: 
3. MRI finding: 
4. Cytology: 
 
 
 
 
AGE SEX I.P NO PAIN ULCER NODULE LYMPHEDEMA RECURRENCE MRI PREDICTABILITY
55 FEMALE 35467 YES NO YES NO YES YES
48 FEMALE 32690 YES NO NO NO
52 FEMALE 41350 YES YES YES NO YES YES
65 FEMALE 27889 NO NO NO YES
39 FEMALE 34589 NO YES YES NO YES YES
54 FEMALE 39021 YES NO NO NO
43 FEMALE 28923 YES YES NO NO YES YES
48 FEMALE 31267 NO NO NO NO
56 FEMALE 30956 YES NO YES NO
68 FEMALE 41590 YES NO NO YES
S.NO NAME AGE SEX IP NO SIDE
NODAL 
DISEASE
CLINICAL 
STAGE
HISTOLOGICAL 
POSITIVITY
HISTOLOGICAL 
TYPE
MAMMOGRA
M 
PREDICTABILIT
Y
BIRARDS 
GRADING
CONTRAL
ATERAL 
INVOLVE
MENT
MRI 
PREDICTAB
ILITY
CONTRALAT
ERAL 
INVOLMENT
PECTORAL 
FASCIAL 
INVOLMENT
OPERATIVE 
MANAGEMENT
1 VIJAYA 47 FEMALE 29755 RIGHT NO 2A YES VASIVE DUCTAL C YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
2 INDRA
28
FEMALE 33518 LEFT YES 3A YES DCIS YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
3 VETHAVALLI 20 FEMALE 34605 RIGHT NO 2A YES DCIS YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
4 RADHIKA 30 FEMALE 35542 RIGHT N0 2B YES VASIVE DUCTAL C YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
5 DEVI 44 FEMALE 35466 LEFT YES 3A YES DCIS YES 6 NO YES NO YES
MRM/ AXILLARY 
CLEARANCE
6 KOWSALYA 54 FEMALE 36635 RIGHT YES 2B YES VASIVE DUCTAL C YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
7 SHANTHI 56 FEMALE 33414 RIGHT NO 2A YES VASIVE DUCTAL C YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
8 RAMYA 28 FEMALE 37741 RIGHT NO 2B YES DCIS YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
9 LAKSHMI 29 FEMALE 41188 LEFT YES 3A YES VASIVE DUCTAL C YES 5 NO YES NO YES
MRM/ AXILLARY 
CLEARANCE
10 NAVANEETHAM 40 FEMALE 43037 RIGHT NO 2A YES VASIVE DUCTAL C YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
11 BALAMMA 40 FEMALE 43014 RIGHT NO 2A YES DCIS YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
12 JANAGI 54 FEMALE 42978 LEFT YES 2A YES AGET'S WITH DC YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
13 GOWRI 50 FEMALE 42226 LEFT NO 2B YES VASIVE DUCTAL C YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
14 BHAVANI 33 FEMALE 47122 RIGHT YES 2B YES VASIVE DUCTAL C YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
15 SARASWATHY 30 FEMALE 47563 RIGHT YES 2B YES VASIVE DUCTAL C YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
16 KUMARI 43 FEMALE 49314 RIGHT NO 2A YES VASIVE DUCTAL C YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
17 PUSHPA 41 FEMALE 42694 RIGHT NO 2A YES VASIVE DUCTAL C YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
18 CHINNAPONNU 38 FEMALE 44640 LEFT YES 3A YES DCIS YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
19 JAMUNA 46 FEMALE 44724 LEFT YES 2B YES DCIS YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
20 LOGA 65 FEMALE 44533 LEFT YES 3A YES VASIVE DUCTAL C YES 6 NO YES NO YES
MRM/ AXILLARY 
CLEARANCE
21 DEVAKI 38 FEMALE 46743 LEFT NO 2A YES DCIS YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
22 RADHA 45 FEMALE 47001 RIGHT YES 2A YES VASIVE DUCTAL C YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
23 KANAGA 45 FEMALE 21483 LEFT NO 2B YES DCIS YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
24 SAIMUNISHA 48 FEMALE 36991 RIGHT YES 3A YES VASIVE DUCTAL C YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
25 PARVEEN 36 FEMALE 38810 RIGHT NO 2A YES DCIS YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
26 USHARANI 45 FEMALE 41327 LEFT NO 2A YES VASIVE DUCTAL C NO 2 NO NO NO NO
MRM/ AXILLARY 
CLEARANCE
27 VELUMANI 49 FEMALE 46018 LEFT NO 2B YES DCIS YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
28 SARASWATHY 34 FEMALE 21335 RIGHT YES 2B YES DCIS YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
29 KALA 47 FEMALE 22406 RIGHT YES 3A YES DCIS YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
30 NIRMALA 45 FEMALE 23086 RIGHT NO 2A YES VASIVE DUCTAL C NO 3 NO NO NO NO
MRM/ AXILLARY 
CLEARANCE
31 GOWRI 50 FEMALE 34746 LEFT YES 3A YES VASIVE DUCTAL C YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
32 NAVANEETHAM 40 FEMALE 42352 RIGHT NO 2A YES DCIS YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
33 VERONIKA 55 FEMALE 44730 LEFT YES 3A YES VASIVE DUCTAL C YES 5 NO YES NO YES
MRM/ AXILLARY 
CLEARANCE
34 HAMSA 34 FEMALE 44571 LEFT NO 2A YES DCIS NO 2 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
35 JANAKI 44 FEMALE 38491 LEFT YES 2B YES VASIVE DUCTAL C YES 5 NO YES NO YES
MRM/ AXILLARY 
CLEARANCE
36 JANAKI 64 FEMALE 33625 LEFT NO 2A YES DCIS YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
37 CHRISTINAMARY 62 FEMALE 41709 LEFT NO 2A YES VASIVE DUCTAL C YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
38 MOGINI 55 FEMALE 43256 RIGHT YES 2B YES DCIS YES 6 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
39 RAVANAMMAL 50 FEMALE 25608 RIGHT YES 3A YES CINOUS CARCINO YES 4 NO YES NO YES
MRM/ AXILLARY 
CLEARANCE
40 INDRANI 45 FEMALE 48921 LEFT NO 2A YES DCIS YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
41 SARITHA 36 FEMALE 34569 LEFT YES 2A YES VASIVE DUCTAL C YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
42 RENUKA 46 FEMALE 32786 RIGHT NO 2A YES VASIVE DUCTAL C YES 6 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
43 LALITHA 37 FEMALE 45803 RIGHT NO 2B YES DCIS YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
44 GOVINDAMMAL 39 FEMALE 34590 LEFT YES 2A YES DCIS YES 6 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
45 CHENGAMMA 42 FEMALE 32489 LEFT NO 2B YES DCIS YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
46 RAJESHWARI 59 FEMALE 38905 RIGHT YES 2B YES VASIVE DUCTAL C YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
47 ANNATHAI 49 FEMALE 45097 LEFT YES 3A YES VASIVE DUCTAL C YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
48 SANGEETHA 54 FEMALE 47823 RIGHT YES 2B YES DCIS YES 4 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE
49 SAKUNTHALA 65 FEMALE 34790 LEFT YES 3A YES VASIVE DUCTAL C YES 6 NO YES NO YES
MRM/ AXILLARY 
CLEARANCE
50 HINNAKOLANTH 68 FEMALE 49201 LEFT YES 2B YES VASIVE DUCTAL C YES 5 NO YES NO NO
MRM/ AXILLARY 
CLEARANCE


